These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 36505818)
1. Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world. Feng JK; Liu ZH; Fu ZG; Chai ZT; Sun JX; Wang K; Cheng YQ; Zhu HF; Xiang YJ; Zhou LP; Shi J; Guo WX; Zhai J; Cheng SQ Front Oncol; 2022; 12():954203. PubMed ID: 36505818 [TBL] [Abstract][Full Text] [Related]
2. Transarterial Chemoembolization Plus Lenvatinib and PD-1 Inhibitors for Hepatocellular Carcinoma with Main Trunk Portal Vein Tumor Thrombus: A Multicenter Retrospective Study. Li SQ; Wu JY; Wu JY; Xie H; Li JH; Zeng ZX; Fu YK; Liu DY; Li H; Chen WZ; Huang JY; Yan ML J Hepatocell Carcinoma; 2023; 10():1799-1811. PubMed ID: 37850080 [TBL] [Abstract][Full Text] [Related]
3. The impact of PD-1 inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a retrospective study. Ding Z; Fang G; Tang Y; Zeng Y Sci Rep; 2024 Jun; 14(1):14334. PubMed ID: 38906915 [TBL] [Abstract][Full Text] [Related]
4. Transarterial chemoembolization plus immune checkpoint inhibitor as postoperative adjuvant therapy for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter cohort study. Yuan L; Feng J; Zhang Y; Lu C; Xu L; Liang C; Liu Z; Mao F; Xiang Y; Wang W; Wang K; Cheng S Eur J Surg Oncol; 2023 Jul; 49(7):1226-1233. PubMed ID: 36739252 [TBL] [Abstract][Full Text] [Related]
5. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features. Zou X; Xu Q; You R; Yin G Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443 [TBL] [Abstract][Full Text] [Related]
6. Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Zou X; Xu Q; You R; Yin G Adv Ther; 2023 Apr; 40(4):1686-1704. PubMed ID: 36805422 [TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma. Liu QQ; Wang XX; Ji H; Dou QY; Zhang HM Med Oncol; 2024 Mar; 41(5):91. PubMed ID: 38526607 [TBL] [Abstract][Full Text] [Related]
8. Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors Versus Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma with First- or Lower-Order Portal Vein Tumor Thrombosis. Zhang JX; Cheng Y; Wei J; Fan WL; Liu J; Zhou CG; Liu S; Shi HB; Chu XY; Zheng WL; Zu QQ Cardiovasc Intervent Radiol; 2024 Jun; 47(6):751-761. PubMed ID: 38671322 [TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world. Xie D; Sun Q; Wang X; Zhou J; Fan J; Ren Z; Gao Q Ann Transl Med; 2021 Apr; 9(8):652. PubMed ID: 33987350 [TBL] [Abstract][Full Text] [Related]
10. Transarterial chemoembolization combined with molecularly targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a retrospective cohort study. Jiang N; Zhong B; Huang J; Li W; Zhang S; Zhu X; Ni C; Shen J Front Immunol; 2023; 14():1205636. PubMed ID: 37583693 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of transarterial chemoembolization-lenvatinib sequential therapy for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study. Chen R; Li Y; Song K; Li L; Shen C; Ma P; Wang Z J Gastrointest Oncol; 2022 Apr; 13(2):780-786. PubMed ID: 35557575 [TBL] [Abstract][Full Text] [Related]
12. Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review. Sun L; Xu X; Meng F; Liu Q; Wang H; Li X; Li G; Chen F Front Oncol; 2022; 12():980214. PubMed ID: 36249023 [TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma. Wang YY; Yang X; Wang YC; Long JY; Sun HS; Li YR; Xun ZY; Zhang N; Xue JN; Ning C; Zhang JW; Zhu CP; Zhang LH; Yang XB; Zhao HT World J Gastroenterol; 2023 Mar; 29(10):1614-1626. PubMed ID: 36970591 [TBL] [Abstract][Full Text] [Related]
14. Anlotinib followed by transarterial chemoembolization and radiofrequency ablation is a safe and effective initial treatment for hepatocellular carcinoma patients with portal vein tumor thrombus: A retrospective case series study. Wang J; Li X; Wang F; Shi D; Zhang J J Cancer Res Ther; 2021 Jul; 17(3):619-624. PubMed ID: 34269290 [TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of HAIC (FOLFOX) combined with lenvatinib plus PD-1 inhibitors vs. TACE combined with lenvatinib plus PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas. Lin Z; Chen D; Hu X; Huang D; Chen Y; Zhang J; Li X; Zou X Am J Cancer Res; 2023; 13(11):5455-5465. PubMed ID: 38058801 [TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: A Single Center Experience. Pan X; Wu SJ; Tang Y; Zhou YF; Luo JW; Fang ZT J Hepatocell Carcinoma; 2023; 10():883-892. PubMed ID: 37324411 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World. Li X; Fu Z; Chen X; Cao K; Zhong J; Liu L; Ding N; Zhang X; Zhai J; Qu Z Front Oncol; 2022; 12():950266. PubMed ID: 35860582 [TBL] [Abstract][Full Text] [Related]
18. A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus. Li X; Ding X; Liu M; Wang J; Sun W; Teng Y; Xu Y; Wu H; Li W; Zhou L; Chen J Cancer Med; 2023 Aug; 12(16):16805-16814. PubMed ID: 37387602 [TBL] [Abstract][Full Text] [Related]
19. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis. Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Zhu LZ; Xu HF; Yang RJ Biomed Res Int; 2021; 2021():6670367. PubMed ID: 34337041 [TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma. Li J; Kong M; Yu G; Wang S; Shi Z; Han H; Lin Y; Shi J; Song J Front Immunol; 2023; 14():1188308. PubMed ID: 37545497 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]